PALB2 and pancreatic neoplasm: Global genomic sequencing has identified a biallelic inactivation of PALB2 in a patient who had advanced gemcitabine-resistant pancreatic cancer; the patient later received mitomycin C (a DNA damaging agent) based on a personalized therapy and responded well for 36 + months (when the expected median survival was 3 months)60.